-
-
We use regular blood bank saline or whatever suspension the reagent RBCs are in (as long as it isn't a LISS suspension). The procedure is just doing a screen/panel/xm don't add enhancement media, and incubate for 30min@ 37C -
-
From my manager's "old school" approach that if a clinically significant antibody is present with a warm auto, it will react alone without enhancement media due to its supposed "high" titer. Similar to slsmith, we incorporate this approach when we have panagglutination in our more sensitive methodologies and are trying to "look through" these reactions. It's never our sole method or what we use to report, but just another arrow in the quiver of techniques.
-
-
-
-
-
-
-
-
-
-
I just answered this question. My Score PASS
-
I just answered this question. My Score FAIL
-
-
carolyn swickard reacted to a post in a topic:
DTT-Treatment of Screening Cells (Daratumumab/Darzalex)
-
-
-
I work at a reference lab as well and we get roughly 3-4 DARA patients a month. More often than not, half are repeat customers. It seems strength varies from patient to patient, but definitely increases as the treatment continues, but nothing more than a 2+. We treat screening cells with DTT every time. We also treat a second set with trypsin to help rule out Kell group system antibodies. So far we haven't had much viability with cells lasting longer than a full shift.
-
What about pre-warming a clinically significant antibody away like an Anti-Vel?
-
I have seen this before, cold auto. We did an auto adsorption at 4C, and reran the sample; like yours, clean as a whistle. And I agree with catchmenow51 about the potential adsorption in transport.
-
We use the same 3 day rule here at our facility.
-
I work at a community blood bank. We have found that the platelet bumps the cancer patients were receiving from the crossmatched platelets were as good, and sometimes better, than from the HLA matched units.
